Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Stock Now Rated “Hold” by Wall Street Analysts

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have been assigned a consensus recommendation of “Hold” from the seven ratings firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and two have given a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $24.80.

A number of research firms recently weighed in on ARTV. TD Cowen downgraded Artiva Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $40.00 price objective on shares of Artiva Biotherapeutics in a report on Friday, October 2nd. Jefferies Financial Group downgraded shares of Artiva Biotherapeutics from a “buy” rating to a “hold” rating and set a $4.00 price target on the stock. in a report on Thursday, October 29th. Wedbush cut shares of Artiva Biotherapeutics from an “outperform” rating to a “neutral” rating and set a $4.00 price target for the company. in a research note on Tuesday, October 27th. Finally, Wall Street Zen cut Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 31st.

Insider Buying and Selling

In other Artiva Biotherapeutics news, insider Christopher Horan sold 10,340 shares of the business’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $6.84, for a total transaction of $70,725.60. Following the transaction, the insider directly owned 312,744 shares of the company’s stock, valued at approximately $2,139,168.96. The trade was a 3.20% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Jennifer Bush sold 8,370 shares of the firm’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $6.84, for a total value of $57,250.80. Following the transaction, the chief operating officer directly owned 366,159 shares of the company’s stock, valued at $2,504,527.56. This represents a 2.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 137,048 shares of company stock valued at $1,086,167 over the last quarter. Company insiders own 1.80% of the company’s stock.

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ARTV. 5AM Venture Management LLC bought a new stake in shares of Artiva Biotherapeutics during the 2nd quarter valued at $22,827,049. Blue Owl Capital Holdings LP bought a new position in shares of Artiva Biotherapeutics during the 2nd quarter valued at approximately $8,483,000. BlackRock Inc. purchased a new position in shares of Artiva Biotherapeutics in the 2nd quarter worth $6,739,000. Nantahala Capital Management LLC purchased a new position in shares of Artiva Biotherapeutics in the 2nd quarter worth approximately $2,910,000. Finally, Alyeska Investment Group L.P. lifted its holdings in shares of Artiva Biotherapeutics by 173.6% in the 2nd quarter. Alyeska Investment Group L.P. now owns 273,615 shares of the company’s stock worth $2,654,000 after acquiring an additional 173,615 shares during the last quarter.

Artiva Biotherapeutics Trading Up 0.5%

ARTV traded up $0.02 during trading on Friday, reaching $4.15. 908,474 shares of the company’s stock were exchanged, compared to its average volume of 1,152,021. Artiva Biotherapeutics has a one year low of $2.96 and a one year high of $14.53. The stock has a market capitalization of $202.89 million, a PE ratio of -1.26 and a beta of 2.67. The firm has a fifty day moving average price of $7.37 and a two-hundred day moving average price of $7.95.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Thursday, August 6th. The company reported ($0.63) EPS for the quarter, meeting the consensus estimate of ($0.63). Sell-side analysts expect that Artiva Biotherapeutics will post -2.71 earnings per share for the current year.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company developing off-the-shelf, allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s approach is intended to provide readily available cell-based treatments that can be manufactured in advance and administered without using each patient’s own cells.

Artiva’s lead product candidate is AlloNK, also known as AB-101, an allogeneic NK cell therapy derived from umbilical cord blood. The company is evaluating AlloNK in combination with antibody treatments, including rituximab, for conditions such as B-cell malignancies and autoimmune diseases.